Results 111 to 120 of about 4,251 (181)

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12. [PDF]

Blood Adv
Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I, Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA, Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V, Varettoni M, Coscia M, Innocenti I.   +31 more
europepmc   +1 more source

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Future Oncol
Shadman M, Chanan-Khan A, Campbell D, Xue M, Massoudi M, Williams R, Yang K, Tam CS.   +7 more
europepmc   +1 more source

Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. [PDF]

Front Oncol
Martinez-Gamboa DA, Beas FF, Moreno-Cortes E, Swanson LA, Mangold AR, Vargas F, Castro JE.   +6 more
europepmc   +1 more source

Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. [PDF]

Blood Adv
Darnell EP, Gallagher KME, Kanska J, Scarfò I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV.   +11 more
europepmc   +1 more source

Brute force: the effects of ibrutinib on brexu-cel. [PDF]

Blood Adv
Peterson CE, Betts BC.
europepmc   +1 more source

Acalabrutinib Regimen [PDF]

, 2020
openaire   +1 more source

Acute Severe Hepatitis B Virus Infection in Previously Vaccinated Patient during Acalabrutinib Treatment. [PDF]

Emerg Infect Dis
Rojek L, Wnuk-Lipinski T, Marek I, Grabowski H, Adrych K.   +4 more
europepmc   +1 more source

Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]

Ann Hematol
Visentin A.
europepmc   +1 more source

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk. [PDF]

Cancers (Basel)
Andreescu M, Tudorache SI, Moldovan CA, Moldovan AD, Cochior D, Popov V, Andreescu B, Ionescu D, Padurariu-Covit MD.   +8 more
europepmc   +1 more source

Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors. [PDF]

Cancers (Basel)
Robak E, Robak T.
europepmc   +1 more source